

**Certificate of Approval of a Supplement**  
**pursuant to Section 28 para. 1 of the German Securities Prospectus Act in**  
**conjunction with Sections 17 and 18 of the German Securities Prospectus Act**  
**in the version in force up to 20 July 2019 transposing Articles 17 and 18**  
**of Directive 2003/71/EC in the version in force up to 20 July 2019**

**To:**

Autoriteit Financiële Markten, The Netherlands  
Autorité des marchés financiers (AMF), France  
CONSOB -Commissione Nazionale per le Società e la Borsa-, Italy  
Comisión Nacional del Mercado de Valores, Spain  
Commission de Surveillance du Secteur Financier, Luxembourg  
Financial Services and Markets Authority, Belgium  
Finanzmarktaufsicht (FMA), Austria  
Finanzmarktaufsicht Liechtenstein, Liechtenstein  
The Financial Conduct Authority (FCA), United Kingdom (UK)

**From:**

**Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin)**  
Federal Financial Supervisory Authority, Germany

We hereby certify that the Supplement (Base prospectus, single document) detailed below has been drawn up in accordance with the German Securities Prospectus Act transposing Directive 2003/71/EC in the version in force up to 20 July 2019 and was approved by us on 27.02.2020. The approval was granted on the basis of an English scrutiny version of the Base Prospectus according to Section 28 para 1 of the German Securities Prospectus Act in conjunction with Section 19 para. 2 of the German Securities Prospectus Act in the version in force up to 20 July 2019.

**Name of Issuer:**

UBS AG

**Registered Office/Seat:**

Switzerland, Zürich, Bahnhofstraße 45

**Type of Securities :**

1. Supplement No. 5 to the Base Prospectus dated 27 March 2019 - Fixed Income Securities (Rates) (relating to LU, BE, AT, LI, GB, NL)
2. Supplement No. 4 to the already published tripartite Prospectus comprising the Summary and Securities Note dated 6 May 2019 and the Registration Document of the UBS AG dated 27 November 2018 for the issuance of 90,000 UBS Open End Certificates (DE000UBS0QD1) (relating to AT, LU)
3. Supplement No. 4 to the already published tripartite Prospectus comprising the Summary and Securities Note dated 8 May 2019 and the Registration Document of the UBS AG dated 27 November 2018 for the issuance of 500,000 Portfolio Certificates to the PTAM Navigator Portfolio (CH0441698849) (relating to LU)
4. Supplement No. 3 to the Base Prospectus dated 13 June 2019 - Warrants and other leveraged Securities (relating to LU, LI, AT, IT)
5. Supplement No. 3 to the Base Prospectus dated 19 June 2019 - Securities (relating to NL, LU, LI, AT, GB, IT)
6. Supplement No. 3 to the Base Prospectus dated 10 July 2019 - Fixed Income Securities (Cash) (relating to NL, LU, LI, AT, GB)
7. Supplement No. 3 to the already published tripartite Prospectus comprising the Summary and Securities Note dated 11 July 2019 and the Registration Document of the UBS AG dated 27 November 2018 for the issuance of Strategy Certificates on Gelfarth Select Strategy (CH0326223960) (relating to AT)
8. Supplement No. 3 to the already published tripartite Prospectus comprising the Summary and Securities Note dated 11 July 2019 and the Registration Document of the UBS AG dated 27 November 2018 for the issuance of Portfolio Certificates linked to Smart Health Care Portfolio (DE000US8MAR5) (relating to LI, AT)
9. Supplement No. 3 to the Base Prospectus of UBS Express Securities, UBS Twin-Win Securities, UBS Speeder Securities, UBS Outperformance Plus Securities, UBS Bonus Securities, UBS Dolphin Securities, UBS Capital Protected Securities and UBS Accumulator Securities (relating to FR, LU, AT, GB, LI, BE, NL, ES, IT)

**References to the annexes of Regulation EC 809/2004 in the version in force up to 20 July 2019 according to which the prospectus was drawn up:**

n.a.

**Guarantor (if any):** n.a.

Yours faithfully,

Kalantzis

**This CoA is valid without signature**

Prospectus Group, Section WA 53  
Federal Financial Supervisory Authority  
Securities Supervision / Asset Management  
Date: 27.02.2020  
Reference: WA 53-Wp 7107-20000469-2020/0011

Attachments:

(1) Supplement

(2) Translations of Summary